The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease

@article{HutterPaier2004TheAI,
  title={The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease},
  author={Birgit Hutter-Paier and Henri J Huttunen and Luigi Puglielli and Christopher B. Eckman and Doo Yeon Kim and Alexander Hofmeister and Robert D. Moir and Sarah B. Domnitz and Matthew P. Frosch and Manfred Windisch and Dora M. Kovacs},
  journal={Neuron},
  year={2004},
  volume={68}
}
Amyloid beta-peptide (Abeta) accumulation in specific brain regions is a pathological hallmark of Alzheimer's disease (AD). We have previously reported that a well-characterized acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor, CP-113,818, inhibits Abeta production in cell-based experiments. Here, we assessed the efficacy of CP-113,818 in reducing AD-like pathology in the brains of transgenic mice expressing human APP(751) containing the London (V717I) and Swedish (K670M/N671L… CONTINUE READING
80 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

Similar Papers

Loading similar papers…